Increasing transparency in partnerships for health - Introducing the Green Light Committee

Tropical Medicine and International Health

Volumn 7, Issue 11, 2002, Pages 970-976

  Gupta, Rajesh ^a   Cegielski, J Peter ^a   Espinal, Marcos A ^a   Henkens, Myriam ^a   Kim, Jim Y ^a   Lambregts Van Weezenbeek, Catherina S B ^a   Lee, Jong Wook ^a   Raviglione, Mario C ^a   Suarez, Pedro G ^a   Varaine, Francis ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Access to drugs; MDR TB; Partnerships; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ACCESSIBILITY; HEALTH CARE; INSTITUTIONAL FRAMEWORK; PARTNERSHIP APPROACH;

ARTICLE; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; INFECTION CONTROL; MEDICAL DECISION MAKING; MULTIDRUG RESISTANCE; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORGANIZATIONAL POLICY; PRIVATE SECTOR; PUBLIC SECTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

ACTINOBACTERIA (CLASS); UNCULTURED ACTINOMYCETE;

EID: 18744374586     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2002.00960.x     Document Type: Article

References (31)

1. Birmingham K (2000) The need for public-private partnerships. Nature Medicine 5, 481.
2. Brugha R, Starling M & Walt G (2002) GAVI, the first steps: Lessons for the Global Fund. Lancet 359, 435-438.
3. Brugha R & Walt G (2001) A global health fund: A leap of faith? British Medical Journal 323, 152-154.
4. Brundtland GH (2001a). American Public Health Association Annual Meeting, 'One World: Global Health'. 22 October 2001, Atlanta, GA, USA. (http://www.who.int/director-general/speeches/2001/english/20011022_ aphaatlanta.en.html).
5. Brundtland GH (2001b) Stop TB Partners Forum: 'Investing in Global Health, A Stop TB Partnership Responsibility'. 23 October 2001, Washington, DC, USA. (http://www.who.int/director-general/speeches/2001/english/20011023_ stoptbforum.en.html).
6. Buse K & Walt G (2000a) Global public-private partnerships: Part I - A new development in health? Bulletin of WHO 78, 549-561.
7. Buse K & Walt G (2000b) Global public-private partnerships: Part II - What are the health issues for global governance? Bulletin of WHO 78, 699-709.
8. Buse K & Waxman A (2001) Public-private health partnerships: A strategy for WHO? Bulletin of WHO 79, 748-754.
9. Cullinan T (2001) Drug-resistant tuberculosis: Desperate measures? Lancet 357, 1124.
10. Donnelly J (2001a) Talks to start amid discord on AIDS war: UN seeks cash, consensus on fighting disease. Boston Globe 25 June 2001.
11. Donnelly J (2001b) Working towards AIDS drugstore for Africa. Boston Globe 17 July 2001.
12. Dye C, Espinal MA, Watt CJ, Mbiaga C & Williams BG (2001) Worldwide incidence of multidrug-resistant tuberculosis. Journal of Infectious Diseases 185, 1197-1202.
13. Farmer P, Leandre F, Mukherjee JS et al. (2001) Community-based approaches to HIV treatment in resource-poor settings. Lancet 358, 404-409.
14. Freeman P (1999) Pan American Health Organization's Revolving Fund. Children Vaccine Commission Working Paper. Children Vaccine Commission, Geneva.
15. Green Light Committee (2002) 2002 Application Review Cycle. International Journal of Tuberculosis and Lung Disease 6, 1.
16. Gupta R, Kim JY, Espinal MA et al. (2001) Responding to market failures in tuberculosis control. Science 293, 1049-1051.
17. Heaton A & Keith R (2002) A Long Way to Go: A Critique of GAVI's Initial Impact. Save the Children UK, London.
18. Lambregts-van Weezenbeek CSB & Reichman LB (2001) DOTS and DOTS-Plus: What's in a name? International Journal of Tuberculosis and Lung Disease 4, 995-996.
19. Lambregts-van Weezenbeek CSB & Veen J (1995) Control of drug-resistant tuberculosis. Tubercle and Lung Disease 76, 455-459.
20. Reich MR (2000) Public-private partnerships for public health. Nature Medicine 6, 617-620.
21. Smith R (2000) Vaccines and medicines for the world's poorest: Public-private partnerships seem to be essential. British Medical Journal 320, 952-953.
22. Society for International Development (2001) Report of the International Seminar on Global Public-Private Partnerships for Health and Equity, 23-24 November 2000, SID, Rome.
23. WHO (1999) Procurement of Second-line Anti-tuberculosis Drugs for DOTS-Plus Pilot Projects (eds R. Gupta, J.G. Brenner, C.L. Henry et al.) WHO, Geneva
24. WHO (2000) Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of Multidrug-Resistant Tuberculosis (MDR-TB). (eds R. Gupta & T. Arnadottir) WHO, Geneva.
25. WHO (2001a) Instructions for Applying to the Green Light Committee for Access to Second-Line Drugs. WHO, Geneva.
26. WHO (2001b) DOTS-Plus and the Green Light Committee. WHO, Geneva.
27. WHO (2001c) Progress in DOTS-Plus and the management of drug-resistant tuberculosis. In: Proceedings of the Meeting of the Working Group on DOTS-Plus for MDR-TB, 25-27 January, 2001 (eds R Gupta & MA Espinal) WHO, Geneva.
28. WHO (2001d) International Coordinating Group (ICG) on Vaccine Provision for Epidemic Meningitis Control. Report of the Sixth Meeting, 20-21 September 2000. WHO, Geneva.
29. WHO (2002) Global Tuberculosis Control: Surveillance, Planning, and Financing. WHO, Geneva.
30. WHO/International Union Against Tuberculosis and Lung Disease (IUATLD) (1997) Anti-Tuberculosis Drug Resistance in the World: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO, Geneva, www.who.int/gtb/policyrd/DOTSplus.html
31. Widdus R (2001) Public-private partnerships for health: Their main targets, their diversity, and their future directions. Bulletin of WHO 79, 713-720.